Enquirer Consulting Group

Reachable Buyer Map

Prepared for Josua Ziegler · Germany and Europe · August 2026
Here is the map. Building software and connected hardware for other people's products means the buyer is never one person: there is the founder or product owner who wants the thing built, the regulatory seat that decides whether it can ship, and inside larger companies a research and development lead who owns the budget for both. This page covers where those seats sit across Germany and the wider European market, the layers they split into, and roughly how many companies sit in each.
German medical technology manufacturers
The closest market to the bench, and the one where a regulated software or connected hardware project cannot be postponed indefinitely. Companies of this size usually carry engineering for the device they already sell rather than for the next one, which is why the connected and software side goes out of house.
Who signs: the head of research and development, the product owner, the regulatory affairs manager, and the managing director at owner-led firms.
1,300 to 1,500
German medical technology companies carrying 20 or more people; the full national register runs to several thousand once micro-companies are counted
Medical technology companies across the rest of Europe
The same buyer in a different jurisdiction, and a market overwhelmingly made of small companies rather than large ones. The reachable slice is the fraction building software or connected hardware rather than instruments and consumables, and no code isolates that slice, so it is filtered by product and by hiring rather than pulled from a register.
Who signs: the head of product or engineering, the quality and regulatory lead, and the founder at companies under 50 people.
33,000 to 35,000
medical technology companies across Europe, the large majority of them small; the German count above sits inside this number and the two are not added
Applications inside Germany's digital health reimbursement directory
The most useful public list in this market. Every application on it has already paid for clinical evidence, regulatory work and a submission, which makes the company behind it a proven buyer of exactly this kind of engineering rather than a possible one. The queue of companies preparing a submission is longer than the directory itself.
Who signs: the founder or managing director, the head of product, and the regulatory consultant already inside the project.
Roughly 50 to 70 listed
applications listed in the national directory, public and dated, plus a longer unlisted queue of companies working toward a submission
Funded digital health, wearable and diagnostics startups across the German-speaking markets
Bought at a moment rather than on a cycle. A round closes, a pilot has a date, an internal build stalls, and a bench that can carry design, firmware and regulatory reading at once becomes urgent for about six weeks. Miss the window and the work goes to whoever was already in the room.
Who signs: the founder, the chief technology officer, and the head of product.
No single register
identified from funding announcements, accelerator cohorts and trade press rather than from any list; the trigger is the value, not the name
Sports technology, connected fitness and performance brands
Your second market, and commercially a separate one. Same sensors, same apps, same data problems, but a different vocabulary, a faster buying cycle and no regulatory gate, so the companies here almost never meet the suppliers who serve the health side.
Who signs: the head of product, the innovation lead, the founder, and the brand's technical director on hardware.
Not enumerated
spread across sporting goods, consumer electronics and software registers with no code that isolates them; identified rather than filtered
Research and innovation units inside larger health, pharma and consumer companies
Slower to open and considerably larger once open. These units buy capacity they cannot hire fast enough, on annual budgets, and they repeat. Worth being straight about the difficulty: the buying unit is a department, not a company, so it is identified one at a time rather than filtered from any list.
Who signs: the head of digital or innovation, the research and development program lead, the procurement seat that papers it, and the internal sponsor who wants it done this year.
A short named list
identified unit by unit inside larger parents; the department is the buyer, the parent company is not

Where the openings are

1
Two markets that never see each other's suppliers. Regulated health and sports technology sit in different associations, different trade press and different events, so a channel built for one of them reaches almost none of the other. Two markets from one bench is an advantage, and it only pays if something is deliberately pointed at both.
2
This work is bought at a moment. A round closing, a regulatory deadline, a connected version of an existing device, an internal build that stalled. Those moments are visible from outside if someone is watching the whole market every week, and invisible if you are waiting for the right founder to remember your name.
3
The reimbursement directory is a public buying list. It names companies that have already spent real money on evidence, regulatory work and submission, it carries dates, and it is short enough to work through by hand. Very few engineering partners work it as a list, which is precisely why it stays open.
4
This is a distribution gap, not a credibility one. Your own site puts the bench past 250 startups since 2017, so the question of whether the work is good is already answered for anyone who reads it. What is missing is the machinery that puts that record in front of several thousand named founders, product owners and engineering leads who have never heard of you, on a schedule, and tracks what comes back. That is the part we build, and we hand it over when it works.
Built from public market data, counts banded deliberately. Company counts come from published European and German sector statistics and from national regulatory listings rather than one central source, so they indicate the size of each layer rather than an exact extract. The German count sits inside the European one and the two are not added. Layers with no register are described rather than counted. It describes the market rather than your business, and there is nothing to buy at the end of it.
ENQUIRER CONSULTING GROUP
enquirerconsulting.com